Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,251.9
-19.6 (-0.60%)

 

  • STI Straits Times Index
    3,251.9
    -19.6 (-0.60%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,514.2
    -1.6 (-0.10%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,677.8
    -612.1 (-2.52%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,413.2
    -42.5 (-1.23%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 666.0M
  • Value: 920.2M
  • Rise: 56
  • Fall: 223
  • Unch: 489

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
DISA0.007-
Sembcorp Marine0.082-
Geo Energy Res0.365-0.005
Beverly JCG0.001-
Shen Yao0.003-
Genting Sing0.730-0.020
Rex Intl0.330+0.010
Mapletree Ind Tr2.530-0.080
Singtel2.490-
CapLand IntCom T1.980-

World Indices

World Indices
Name Last Change
Nasdaq 13,542.1 +2.8
HSI 23,684.5 -605.4
HSCEI 8,263.8 -248.5
Jakarta 6,588.8 -12.0
Nikkei 225 27,011.3 -120.0
SSE Comp 3,413.8 -41.9
Shanghai A 3,577.5 -43.9
Shanghai B 279.4 -1.2
KOSPI 2,617.8 -91.5

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CHROMADEX CORPORATION CHROMADEX CORPORATION
Updated on 26 Jan 2022 (End of trading day)
Last (USD): 2.760 Change: -0.050 High: 3.080 Remarks: -
Change (%): -1.78 Low: 2.730
Open 2.850 Yesterday's Close 2.8099999999999996
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 1,383,959 Cumulative Value

Company Background

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.29176 Trailing EPS (USD) b -0.40854 NAV (USD) c 0.5191
PE a - Trailing PE d - Price / NAV c 5.3169
Dividend Yield (%) e - Cash In Hand (USD) f 0.4847 Issued & Paid-up Shares g 68,291,500
Piotroski F Score 2 Market Cap (M) 188.485 Free Float (%) 56.6
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i 14.471
Net Earnings Growth (%) j -23.010 Net Debt/Equity k Net Cash
Sector & Industry Process Industries - Chemicals: Specialty
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 04 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.190
-6.44 %
10 Days --0.340
-10.97 %
20 Days --1.120
-28.87 %
Medium Term Return 3 Months --3.390
-55.12 %
6 Months --6.170
-69.09 %
1 Year --2.100
-43.21 %
Long Term Return 2 Years --1.530
-35.66 %
3 Years --0.570
-17.12 %
5 Years --0.080
-2.82 %
Annualised Return Annualised --
-0.57 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

More Information Available

More information is available to our subscribers, including:

  • Consensus Estimates
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.